Novel molecular insights into RhoA GTPase-induced resistance to aqueous humor outflow through the trabecular meshwork.
Impaired drainage of aqueous humor through the trabecular meshwork (TM) culminating in increased intraocular pressure is a major risk factor for glaucoma, a leading cause of blindness worldwide. Regulation of aqueous humor drainage through the TM, however, is poorly understood. The role of RhoA GTPase-mediated actomyosin organization, cell adhesive interactions, and gene expression in regulation of aqueous humor outflow was investigated using adenoviral vector-driven expression of constitutively active mutant of RhoA (RhoAV14). Organ-cultured anterior segments from porcine eyes expressing RhoAV14 exhibited significant reduction of aqueous humor outflow. Cultured TM cells expressing RhoAV14 exhibited a pronounced contractile morphology, increased actin stress fibers, and focal adhesions and increased levels of phosphorylated myosin light chain (MLC), collagen IV, fibronectin, and laminin. cDNA microarray analysis of RNA extracted from RhoAV14-expressing human TM cells revealed a significant increase in the expression of genes encoding extracellular matrix (ECM) proteins, cytokines, integrins, cytoskeletal proteins, and signaling proteins. Conversely, various ECM proteins stimulated robust increases in phosphorylation of MLC, paxillin, and focal adhesion kinase and activated Rho GTPase and actin stress fiber formation in TM cells, indicating a potential regulatory feedback interaction between ECM-induced mechanical strain and Rho GTPase-induced isometric tension in TM cells. Collectively, these data demonstrate that sustained activation of Rho GTPase signaling in the aqueous humor outflow pathway increases resistance to aqueous humor outflow through the trabecular pathway by influencing the actomyosin assembly, cell adhesive interactions, and the expression of ECM proteins and cytokines in TM cells.
Zhang
Min
M
Dept. of Ophthalmology, Duke Univ. School of Medicine, 2351 Erwin Rd., Durham, NC 27710, USA.
Maddala
Rupalatha
R
Rao
Ponugoti Vasantha
PV
D000199:Actins / Q000378:metabolism; D000818:Animals; D001082:Aqueous Humor / Q000201:enzymology*; D002448:Cell Adhesion; D002478:Cells, Cultured; D016207:Cytokines / Q000235:genetics / Q000378:metabolism; D003599:Cytoskeleton / Q000201:enzymology*; D016326:Extracellular Matrix Proteins / Q000235:genetics / Q000378:metabolism; D022001:Focal Adhesions / Q000201:enzymology; D020869:Gene Expression Profiling; D018014:Gene Transfer Techniques; D006801:Humans; D007429:Intraocular Pressure; D009154:Mutation; D018994:Myosin Light Chains / Q000378:metabolism; D009924:Organ Culture Techniques; D010766:Phosphorylation; D022502:Stress Fibers / Q000201:enzymology; D013552:Swine; D013997:Time Factors; D014129:Trabecular Meshwork / Q000201:enzymology*; D015854:Up-Regulation; D020742:rhoA GTP-Binding Protein / Q000235:genetics / Q000378:metabolism*
D000199:Actins; D016207:Cytokines; D016326:Extracellular Matrix Proteins; D018994:Myosin Light Chains; D020742:rhoA GTP-Binding Protein
Genes Dev. 1997 Sep 15;11(18):2295-322
9308960
BioDrugs. 2007;21(3):167-77
17516712
Invest Ophthalmol Vis Sci. 2004 Jul;45(7):2263-71
15223804
Prog Retin Eye Res. 2005 Sep;24(5):612-37
15919228
Curr Opin Ophthalmol. 2006 Apr;17(2):168-74
16552252
FASEB J. 2006 May;20(7):811-27
16675838
Trends Cell Biol. 2006 Apr;16(4):213-23
16529933
Biochim Biophys Acta. 2005 Dec 30;1754(1-2):245-52
16213195
Nature. 1997 Oct 30;389(6654):990-4
9353125
Curr Opin Cell Biol. 2006 Oct;18(5):472-81
16930976
Am J Physiol Cell Physiol. 2003 Mar;284(3):C627-39
12409284
J Cell Biol. 1998 Apr 20;141(2):539-51
9548730
J Mol Med (Berl). 2002 Oct;80(10):629-38
12395147
Mol Vis. 2002 Mar 06;8:32-44
11889464
Lancet. 2004 May 22;363(9422):1711-20
15158634
Invest Ophthalmol Vis Sci. 1998 Dec;39(13):2649-58
9856774
Mol Vis. 2006 Sep 30;12:1117-26
17093396
Invest Ophthalmol Vis Sci. 2001 Apr;42(5):1029-37
11274082
Physiol Rev. 2003 Oct;83(4):1325-58
14506307
Am J Physiol Cell Physiol. 2004 Mar;286(3):C518-28
14761883
Invest Ophthalmol Vis Sci. 1999 Jan;40(1):74-81
9888429
Mol Vis. 2005 Sep 23;11:798-810
16205625
Nature. 2002 Dec 12;420(6916):629-35
12478284
Invest Ophthalmol Vis Sci. 2000 Mar;41(3):619-23
10711672
Arterioscler Thromb Vasc Biol. 2005 Sep;25(9):1767-75
16002741
Prog Retin Eye Res. 2003 Jul;22(4):435-63
12742391
Invest Ophthalmol Vis Sci. 1990 Nov;31(11):2384-8
2243003
Exp Eye Res. 2005 Jul;81(1):1-4
15978248
Acta Physiol Scand. 1998 Dec;164(4):483-93
9887971
Prog Retin Eye Res. 2000 May;19(3):271-95
10749378
Science. 1997 Jan 31;275(5300):668-70
9005853
Invest Ophthalmol Vis Sci. 2007 Mar;48(3):1191-200
17325163
Invest Ophthalmol Vis Sci. 2000 Dec;41(13):4163-8
11095610
Trends Pharmacol Sci. 2006 Feb;27(2):97-104
16376997
Am J Physiol. 1999 Aug;277(2):C330-42
10444410
Mol Vis. 2005 Apr 27;11:288-97
15889013
Invest Ophthalmol Vis Sci. 2006 Jan;47(1):226-34
16384967
Exp Eye Res. 2005 Feb;80(2):197-206
15670798
Scand J Med Sci Sports. 2005 Aug;15(4):223-30
15998339
Trends Pharmacol Sci. 2001 Jan;22(1):32-9
11165670
Mol Vis. 2004 Oct 07;10:750-7
15496827
FASEB J. 2006 Mar;20(3):536-8
16396994
Exp Eye Res. 1994 Dec;59(6):723-7
7698265
J Appl Physiol (1985). 2001 Jul;91(1):497-503
11408468
Graefes Arch Clin Exp Ophthalmol. 1997 Sep;235(9):551-2
9342603
Invest Ophthalmol Vis Sci. 2001 Jan;42(1):137-44
11133858
Surv Ophthalmol. 1996 Mar-Apr;40(5):379-90
8779084
Vascul Pharmacol. 2002 Nov;39(4-5):187-99
12747959
Invest Ophthalmol Vis Sci. 2005 Aug;46(8):2857-68
16043860
Invest Ophthalmol Vis Sci. 2002 Nov;43(11):3455-64
12407156
Prog Retin Eye Res. 1999 Jan;18(1):91-119
9920500
Invest Ophthalmol Vis Sci. 1998 Sep;39(10):1804-12
9727403